# Progress Note 06 — Preventive Visit

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Judy Garland (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML005-SYN-TD
- Date: 1955-09-28
- Fictional facility: St. Posthumous Health Center
- Fictional author: Margaret Ellsworth-Diaz, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Preventive Visit
- Services: CPT 99395 (periodic preventive medicine, established patient, age 18 to 39) with CPT 99497 (advance care planning), both on the same day

## Chief complaint

Periodic adult preventive visit. **S**

## History of present illness

Ms. Garland is a 33-year-old singer and actor with a barbiturate use disorder on a phenobarbital taper, a mild stimulant use disorder in early remission, chronic insomnia, and depression with anxiety on sertraline, who comes for her yearly preventive visit four weeks after her ten-week review and six months after the birth of her third child. She has followed the written taper schedule: the step two weeks ago went smoothly, and today is her next planned step, to 40.5 mg a day. She has taken no secobarbital, dextroamphetamine, or any other sedative or stimulant. She sleeps about six hours on most nights with her CBT-I routine and a fixed wake time, even after late rehearsals. Her mood and worry are better, and her PHQ-9 today is 7. She eats three meals on most days. She is due for her second contraceptive injection. She still smokes about ten cigarettes a day. **S**

| Element | Detail |
|---|---|
| Visit | Periodic adult preventive visit, age 33 |
| Phenobarbital | 48.6 mg a day; step to 40.5 mg a day today per the written schedule |
| Other sedatives or stimulants | None |
| Sleep | About six hours on most nights |
| Mood | PHQ-9 7; item 9 scored 0 |
| Medicines | Phenobarbital 16.2 mg tablets on the taper schedule; sertraline 50 mg daily; medroxyprogesterone injection every 13 weeks |

## Health risk assessment

Completed by the patient on a tablet in the waiting room and reviewed with her by Dr. Ellsworth-Diaz. **S**

| Domain | Finding |
|---|---|
| Self-rated health | Good, and better than in the summer |
| Psychosocial | Busy with work and three children, with help at home; weekly psychotherapy; a close friend she confides in |
| Substance use | Prescribed phenobarbital on a taper only; no other sedatives or stimulants; a glass of wine a week before the taper and none since |
| Tobacco | About ten cigarettes a day |
| Physical activity | Rehearsals and dance practice most days; walks on days off |
| Nutrition | Three meals on most days and snacks around rehearsals |
| Sleep | About six hours on most nights |
| Sexual and reproductive health | Not planning a pregnancy; on injectable contraception |
| Safety at home | Feels safe at home; no one hurts or threatens her |
| Road safety | Wears a seat belt; does not drive after evening doses |
| Activities of daily living | Independent |
| Oral health | Dental visit in the past year |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever or night sweats; weight up gradually, which she is comfortable with |
| Eyes | Negative | No vision change |
| Ears, nose, mouth, and throat | Negative | Voice fully recovered since the laryngitis |
| Cardiovascular | Negative | No chest pain or palpitations |
| Respiratory | Negative | No cough or breathlessness |
| Gastrointestinal | Negative | No abdominal pain or change in bowel habit |
| Genitourinary | Negative | Irregular light spotting on the injection; no pelvic pain |
| Musculoskeletal | Negative | No joint pain |
| Integumentary | Negative | No rash |
| Neurological | Negative | No tremor, unsteadiness, or seizure-like episodes |
| Psychiatric | Negative | Mood better; PHQ-9 7; no thoughts of suicide or self-harm; no cravings for secobarbital |

11 systems reviewed. **S**

## Current medications

- Sertraline 50 mg oral tablet, one tablet daily **S**
- Phenobarbital 16.2 mg oral tablet on a written taper schedule in two or three divided doses: 81 mg a day from the four-week visit, lowered by 8.1 to 16.2 mg about every two weeks and paused when needed; dispensed two weeks at a time **S**
- Medroxyprogesterone acetate 150 mg/mL injection, 150 mg into the muscle every 13 weeks **S**

## Allergies

- No known allergy **S**

## Objective

BP 110/70 mmHg; pulse 70 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 49.4 kg; BMI 21.7 kg/m². All vital signs are synthetic.

PHQ-9: 7. All results are synthetic.

## Change since baseline

- PHQ-9: 14 at baseline, 7 at this visit **S**

## Immunizations given today

- Influenza vaccine, inactivated, this season **S**

## Physical examination

| System | Finding |
|---|---|
| Constitutional | Well; weight 49.4 kg, BMI 21.7; blood pressure 110/70; pulse 70 |
| Eyes | No nystagmus |
| Neck | No thyroid enlargement or nodes |
| Cardiovascular | Regular rhythm; no murmur |
| Respiratory | Clear to auscultation bilaterally |
| Abdomen | Soft and non-tender |
| Skin | No rash |
| Neurological | No tremor; gait and finger-to-nose testing normal |
| Psychiatric | Bright and engaged; no signs of sedation or withdrawal |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Periodic adult preventive visit completed**. Health risk assessment reviewed and the prevention plan updated. HIV, hepatitis C and hepatitis B screening are due once; cervical screening is up to date. **S**
   - Next preventive visit in one year.
2. **Barbiturate use disorder on a phenobarbital taper** (F13.20). Following the schedule without withdrawal signs. Safety reviewed: no thoughts of suicide or self-harm; the supply is kept in a locked box, and she has the 988 Suicide & Crisis Lifeline in her phone. **S**
   - Lower phenobarbital to 40.5 mg a day today (16.2 mg morning and 24.3 mg at bedtime).
   - Next step in two weeks if she is well; four-month review in four weeks.
3. **Contraception on an enzyme-inducing drug** (Z30.013). Second medroxyprogesterone injection due; light spotting is common and expected. **S**
   - Medroxyprogesterone 150 mg intramuscularly today.
   - Calcium and vitamin D from food; weight-bearing exercise.

## Personalized prevention plan

A written copy was given to the patient. **S**

| Service | Status | Detail |
|---|---|---|
| Blood pressure screening | Completed today | 110/70 mmHg |
| Cervical cancer screening | Up to date | Normal cervical cytology with HPV testing during prenatal care last year; next in five years |
| HIV screening | Ordered | Once for all adults; drawn today with her agreement |
| Hepatitis C screening | Ordered | Once for all adults; drawn today |
| Hepatitis B screening | Ordered | Triple panel once for all adults; drawn today |
| Chlamydia and gonorrhea screening | Not indicated | Age over 24 with one long-term partner and no new risk |
| Intimate partner violence screening | Completed today | Negative; she feels safe at home |
| Depression screening | Completed today | PHQ-9 7, from 14 at intake; item 9 scored 0; in treatment |
| Unhealthy alcohol and drug use | Up to date | AUDIT-C 2 and DAST-10 6 at intake; in treatment; no alcohol during the taper |
| Tobacco cessation | Declined | About ten cigarettes a day; nicotine replacement and counseling offered; she would like to finish the taper first and will be asked again at the next visit |
| Contraception | Completed today | Second medroxyprogesterone injection; phenobarbital does not weaken it |
| Diabetes and cholesterol screening | Not indicated | Diabetes screening begins at 35 for adults with overweight; statin assessment begins at 40 |
| Breast and colorectal cancer screening | Not indicated | Begin at 40 and 45 |
| Influenza vaccine, this season | Completed today | Given today |
| COVID-19 vaccine, this season | Declined | Discussed; she will decide at the next visit |
| Tetanus, diphtheria, and pertussis | Up to date | Tdap at intake |
| HPV vaccine | Declined | Shared decision-making for adults 27 to 45; she chose not to have it |

## Advance care planning

Voluntary advance care planning discussion of about 17 minutes, with her consent. She named a health care agent, and a health care proxy form was completed; the agent is recorded in the chart and is not named here. She said that what matters most to her is her children, her work, and being treated as a person rather than a problem. She asked that, if she were ever too ill to speak for herself, her treatment for the pills be continued without blame. She chose not to record specific treatment preferences today. The plan will be revisited yearly or after any serious illness. **S**

## Guideline basis

- Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025), American Society of Addiction Medicine and nine partner organizations (J Gen Intern Med 2025;40(12):2814-2859)
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge
- Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026), Aether Forge
- USPSTF A and B Recommendations (2026), U.S. Preventive Services Task Force
- Adult Immunization Schedule by Age (2026), Centers for Disease Control and Prevention

## Follow-up

- Four-month review in four weeks with blood count, ferritin, metabolic panel and liver tests. HIV, hepatitis C and hepatitis B results by phone. Next contraceptive injection in 13 weeks. Next preventive visit in one year. **S**
- Next scheduled visit 1955-10-26: four-month review: phenobarbital taper, sleep, mood, laboratory checks and the plan to finish. **S**
